ArticleFrontiers in oncology2026
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study a to evaluate the cost-effectiveness of ramucirumab plus paclitaxel as a switch maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer, from the perspective of the Chinese healthcare system, to guide clinical decision-making and reimbursement policies. Methods: A three-state Markov model (progression-free, progressed disease, and death) was developed based on data from the ARMANI phase III randomized controlled trial. Two treatment strategies were compared: ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy (FOLFOX/CAPOX). Cost data were obtained from national procurement platforms and published literature; utility values were derived from EQ-5D instruments. A willingness-to-pay (WTP) was set at three times China's 2024 per capita GDP, equivalent to USD 40, 457.32 per QALY.Base-case analysis, one-way and probabilistic sensitivity analyses, threshold price analysis, and a patient assistance program (PAP) scenario were conducted. Results: The base-case analysis yielded an incremental cost-effectiveness ratio (ICER) of USD 138, 320.14/QALY, which exceeded the WTP threshold. Under the PAP scenario (i.e., "buy two, get one free"), the ICER was reduced to USD 95, 304.89/QALY, but remained above the threshold. Sensitivity analyses showed the model was most sensitive to utility values, discount rates, and drug price. Threshold analysis suggested that the price of ramucirumab would need to be reduced to approximately 24% of its current level (~USD 149/100mg) to achieve cost-effectiveness; even under the PAP scenario, a further price cut to 36% (~USD 223/100 mg) would still be required. Conclusion: At current pricing and under the existing PAP framework, ramucirumab plus paclitaxel is not a cost-effective switch maintenance strategy in advanced HER2-negative gastric or gastroesophageal junction cancer in China. Significant price reductions through national negotiations may enable this regimen to become economically viable within the Chinese healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.